| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non–Small-Cell Lung Cancer
|
Swaminath, Anand
|
|
2016
|
17 |
2 |
p. 142-149
8 p.
|
artikel
|
| 2 |
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
|
Zhou, Caicun
|
|
2016
|
17 |
2 |
p. 119-127
9 p.
|
artikel
|
| 3 |
Cancer-Related Hyponatremia: Enhancing Recognition and Improving Management
|
Castillo, Jorge J.
|
|
2016
|
17 |
2 |
p. e29-
1 p.
|
artikel
|
| 4 |
CT Characteristics and Survival in Lung Adenocarcinoma
|
Satoh, Hiroaki
|
|
2016
|
17 |
2 |
p. e23-
1 p.
|
artikel
|
| 5 |
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database
|
Lara Jr., Primo N.
|
|
2016
|
17 |
2 |
p. 113-118.e2
11688 p.
|
artikel
|
| 6 |
Editorial Board
|
|
|
2016
|
17 |
2 |
p. A7-
1 p.
|
artikel
|
| 7 |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
|
Boye, Mark
|
|
2016
|
17 |
2 |
p. 150-160
11 p.
|
artikel
|
| 8 |
Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma
|
Lou, Yanyan
|
|
2016
|
17 |
2 |
p. e5-e11
nvt p.
|
artikel
|
| 9 |
Long-Term Survival of a Patient With Non–Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene
|
Myall, Nathaniel J.
|
|
2016
|
17 |
2 |
p. e17-e21
nvt p.
|
artikel
|
| 10 |
Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials
|
Giuliani, Jacopo
|
|
2016
|
17 |
2 |
p. 91-94
4 p.
|
artikel
|
| 11 |
Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer
|
Brade, Anthony
|
|
2016
|
17 |
2 |
p. 133-141
9 p.
|
artikel
|
| 12 |
Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer
|
Weiss, Jared M.
|
|
2016
|
17 |
2 |
p. 128-132
5 p.
|
artikel
|
| 13 |
Risk Prediction Models for Lung Cancer: A Systematic Review
|
Gray, Eoin P.
|
|
2016
|
17 |
2 |
p. 95-106
12 p.
|
artikel
|
| 14 |
Second-Line Treatment in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|
Giuliani, Jacopo
|
|
2016
|
17 |
2 |
p. e25-e27
nvt p.
|
artikel
|
| 15 |
Second Primary Lung Adenocarcinoma Harboring EML4-ALK After Surgically Resected EGFR Positive Lung Adenocarcinoma
|
Takenaka, Tomoyoshi
|
|
2016
|
17 |
2 |
p. e13-e15
nvt p.
|
artikel
|
| 16 |
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)
|
Jänne, Pasi A.
|
|
2016
|
17 |
2 |
p. e1-e4
nvt p.
|
artikel
|
| 17 |
Surgery for Stage IIIA Non–Small-cell Lung Cancer: Lack of Predictive and Prognostic Factors Identifying Any Subgroup of Patients Benefiting From It
|
Jeremić, Branislav
|
|
2016
|
17 |
2 |
p. 107-112
6 p.
|
artikel
|
| 18 |
Table of Contents
|
|
|
2016
|
17 |
2 |
p. A8-A11
nvt p.
|
artikel
|
Tijdschrift beschrijving